You can expect a variety of topics this week, including:
FDA accepts pembrolizumab as singlea agent for treatment of advanded endometrial cancer
New biomarker could predict immunotherapy benefit in breast cancer
New Hampshire's abortion restrictions
Oral contraceptives and risk of cardiac events in women with congenital long-QT syndrome
The impact of nutrition on gynecological diseases